We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0805 | 3.85% | 2.1705 | 2.17 | 2.18 | 2.20 | 2.08 | 2.08 | 117,402 | 15:08:41 |
(Exact Name of Registrant as Specified in its charter)
|
||
Israel
|
N/A
|
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
Identification No.)
|
Copies to:
|
|
Daniel I. Goldberg, Esq.
|
Donna Gershowitz
|
Cooley LLP
|
Compugen Ltd.
|
1114 Avenue of the Americas
46
th
Floor
|
26 Harokmim Street
Building D
|
New York, NY 10036-7798
|
Holon, 5885849
, Israel
|
Tel: 212-479-6000
|
Tel: 972-3-765-8585
|
Fax: 212 479 6275
|
Fax: 972-3-765-8555
|
Large accelerated filer
☐
|
Accelerated filer ☒
|
Non-accelerated filer
☐
|
Smaller reporting company
☐
|
Emerging growth company
☐
|
Title of Each Class Of Securities
To Be Registered
|
Amount To
Be Registered
(1)
|
Proposed Maximum Offering Price Per Share
|
Proposed Maximum Aggregate Offering Price
|
Amount Of
Registration Fee
|
||||||||||||
Ordinary Shares, nominal (par) value NIS 0.01 per share
|
1,700,000
|
(2)
|
$
|
4.21
|
(3)
|
$
|
7,157,000
|
(3)
|
$
|
891.05
|
(1) |
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional ordinary shares that may become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding ordinary shares of the registrant.
|
(2) |
Represents an additional 1,700,000 ordinary shares issuable under the Compugen Ltd. 2010 Share Incentive Plan (the “2010 Plan”), over and above the number of ordinary shares issuable under the 2010 Plan that were previously registered under the Securities Act.
|
(3) |
Pursuant to Rule 457(h)(1) under the Securities Act, the proposed maximum offering price per security and the proposed maximum aggregate offering price are based on the average of the high and low sale prices per share of the registrant’s ordinary shares as reported by The Nasdaq Global Market on March 21, 2018.
|
(i) |
The Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017, filed with the Commission on March 27, 2018 (File No. 000-30902);
|
(ii) |
The Registrant’s Reports of Foreign Private Issuer on Form 6-K, as filed with the Commission on January 31, 2018, February 6, 2018, February 21, 2018 and March 14, 2018 (File No. 000-30902); and
|
(iii) |
The description of the Registrant’s Ordinary Shares in the Registrant’s Registration Statement on Form 8-A (File No. 000-30902) filed with the Commission under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on August 2, 2000, including any amendment or report filed for the purpose of updating such description.
|
EXHIBIT NO.
|
EXHIBIT
|
5.1
|
Opinion of Shibolet & Co., Law Offices
|
23.1
|
Consent of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global
|
23.2
|
Consent of Shibolet & Co., Law Offices (included in Exhibit 5.1)
|
24.1
|
Powers of Attorney (included in the signature pages to this Registration Statement)
|
Compugen Ltd. | |||
|
By:
|
/s/ Anat Cohen-Dayag, Ph.D. | |
Anat Cohen-Dayag, Ph.D. | |||
Chief Executive Officer and President |
Signature
|
Title(s)
|
Date
|
/s/ Anat Cohen-Dayag, Ph.D
Anat Cohen-Dayag, Ph.D.
|
Chief Executive Officer and President and Director
(principal executive officer)
|
March 27, 2018
|
/s/ Ari Krashin
Ari Krashin
|
Chief Financial Officer
(principal financial and accounting officer)
|
March 27, 2018
|
/s/Paul Sekhri
Paul Sekhri
|
Chairman of the Board
|
March 27, 2018
|
/s/ Prof. Yair Aharonowitz
Prof. Yair Aharonowitz
|
Director
|
March 27, 2018
|
/s/ Prof. Ruth Arnon
Prof. Ruth Arnon
|
Director
|
March 27, 2018
|
/s/ Dov Hershberg
Dov Hershberg
|
Director
|
March 27, 2018
|
/s/ Arie Ovadia, Ph.D.
Arie Ovadia, Ph.D.
|
Director
|
March 27, 2018
|
/s/ Dr. Michal Preminger
Dr. Michal Preminger
|
Director
|
March 27, 2018
|
EXHIBIT NO.
|
EXHIBIT
|
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions